FDA Approves Sublingual, Nonopioid Daily Treatment for Fibromyalgia, Tonmya
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 20, 2025 -- The U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine hydrochloride) sublingual tablets for the treatment of fibromyalgia in adults.
The approval is the first for a fibromyalgia treatment in more than 15 years. It is a first-in-class, nonopioid, once-daily bedtime analgesic.
The approval was based on two phase 3 clinical trials of nearly 1,000 patients, which showed that Tonmya significantly reduced daily pain scores versus placebo at 14 weeks. Compared with those receiving placebo, a greater percentage of participants taking Tonmya experienced a clinically meaningful (≥30 percent) improvement in their pain after three months. Across three phase 3 trials involving more than 1,400 patients, Tonmya was generally well tolerated, with the most common adverse events (incidence, ≥2 percent) being numbness in the mouth, oral discomfort, abnormal product taste, drowsiness, tingling or burning in the mouth, oral pain, fatigue, dry mouth, and aphthous canker sores.
"At Tonix, we recognized the transformative potential of pursuing a new approach with Tonmya for fibromyalgia, a chronic overlapping pain condition that has gone without innovation for many years," Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, said in a statement. "We are hopeful that effectively treating pain with Tonmya could help improve the lives of people with this chronic syndrome."
Approval of Tonmya was granted to Tonix Pharmaceuticals.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Chatbots Give Users 'Inconsistent' Info on Suicide, Study Finds
WEDNESDAY, Sept. 3, 2025 — Many people with suicidal thoughts are turning to artificial intelligence (AI) chatbots for comfort and advice, and these programs might not be...
Jim O’Neill Steps in as Acting CDC Chief Amid Firing, Resignations
TUESDAY, Sept. 2, 2025 — The U.S. Centers for Disease Control and Prevention (CDC) is entering a transition period as Jim O’Neill, deputy secretary at the Department...
'Reborn Again': Blind Bride-To-Be Thriving After Triple-Organ Transplant
TUESDAY, Sept. 2, 2025 — Stricken with cancer in infancy, Jessica Lopez endured tumor-fighting treatments that saved her young life but also left her with lasting heart...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.